Morgan Stanley Maintains Overweight on Merck & Co, Lowers Price Target to $177

Benzinga · 3d ago
Morgan Stanley analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $179 to $177.